fig3

Intravenous immunoglobulin use and in-hospital outcomes in adult fulminant myocarditis: a two-center retrospective cohort study

Figure 3. Exploratory dose- and timing-stratified outcomes among IVIG-treated patients. (A) Kaplan-Meier survival curves among patients who received IVIG plus methylprednisolone and MCS, stratified by cumulative IVIG dose (< 10 g, n = 15; 10 to < 20 g, n = 59; ≥ 20 g, n = 71). (B) Aalen-Johansen cumulative incidence of ALI/AKI in the same MCS-treated dose groups. (C) Aalen-Johansen cumulative incidence of successful ECMO weaning with survival to discharge among ECMO-supported patients receiving IVIG plus methylprednisolone, stratified by cumulative IVIG dose (< 10 g, n = 9; 10 to < 20 g, n = 16; ≥ 20 g, n = 36). (D) Kaplan-Meier survival curves in the ≥ 10 g subgroup, stratified by IVIG initiation within 4 days of admission versus later initiation (≤ 4 days, n = 60; > 4 days, n = 70). (E) Kaplan-Meier survival curves in the < 10 g subgroup, stratified by treatment timing (≤ 4 days, n = 9; > 4 days, n = 6). (F) Aalen-Johansen cumulative incidence of ALI/AKI in the ≥ 20 g subgroup, stratified by treatment timing (≤ 4 days, n = 28; > 4 days, n = 43). (G) Aalen-Johansen cumulative incidence of ALI/AKI in the 10 to < 20 g subgroup, stratified by treatment timing (≤ 4 days, n = 32; > 4 days, n = 27). (H) Aalen-Johansen cumulative incidence of ALI/AKI in the < 10 g subgroup, stratified by treatment timing (≤ 4 days, n = 9; > 4 days, n = 6). (D-H) were restricted to patients receiving IVIG plus methylprednisolone and MCS. For the timing-stratified survival analyses in (D and E), cumulative IVIG dose was displayed as < 10 g versus ≥ 10 g, whereas the original three dose categories were retained for the ALI/AKI analyses in (F-H). Day 4 was measured from hospital admission. For ALI/AKI cumulative-incidence analyses, in-hospital death before ALI/AKI and discharge alive without prior ALI/AKI were treated as competing events. For (C), death before qualifying for successful ECMO weaning was treated as a competing event. Displayed P values are from log-rank tests for ( A, D, and E) and Gray's tests for (B, C, and F-H). Patients discharged alive in the Kaplan-Meier analyses were censored on their actual discharge dates, and the displayed numbers at risk were generated directly from the corresponding survival objects.

The Journal of Cardiovascular Aging

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/